Icon Spine biopharma

Spine Diseases We Look To Provide Relief

Chronic back pain relief

Chronic Low Back Pain Resulting from Degenerative Disc Disease

266 million individuals around the world are diagnosed with Degenerative Disc Disease, or DDD, and its associated Chronic Low Back Pain each year.

Chronic low back pain (CLBP) is a complex and frustrating problem. For 266 million worldwide sufferers of CLBP, it affects all aspects of their daily life. For CLBP sufferers, the treatment gap between conservative care and surgery is extreme. Few viable and reliable treatment options exist after a CLBP patient has failed conservative care. Opioids are prevalent, in part, because there are inadequate early-stage treatment solutions for CLBP sufferers. We hope to change this treatment paradigm by addressing an underlying source of pain, degenerative disc disease (DDD).

DDD of the lumbar, or lower spine is a significant cause of disability in the world and a tremendous expense to the healthcare system.  It is associated with a variety of clinical symptoms, including, weakness, low back pain and disability of varying levels of severity. There is currently no treatment for the underlying cause of DDD [Learn more about DDD] and current approaches are aimed at managing pain through a variety of approaches that include physical therapy, chiropractic care, over the counter medications like non-steroidal anti-inflammatory drugs (NSAIDS) or prescription opioids. 

For patients with moderate to severe pain that persists chronically, treatment plans include epidural steroid injections, nerve blocks, radiofrequency ablation or surgical intervention.  Clinical outcomes vary and often do not provide predictable benefit.  Given the substantial costs, pain, and disability associated with DDD, and the current lack of an approved disease-modifying agent, a therapy that could relieve pain and increase function with the potential to mediate the progression of DDD or achieve a regenerative effect could revolutionize the standard of care.

Lumbar Spinal Stenosis

100 million individuals around the world are diagnosed with Lumbar Spinal Stenosis each year.


Lumbar Spinal Stenosis (LSS) is an age-related progressive spinal disease that results in the narrowing of the spinal canal and the compression of the spinal cord and spinal nerves traveling through to the lower back into the legs. There are limited or no early-stage treatment options for LSS, other than palliative care.[Learn More about LSS].


Our LSS Development Program SB-017 and SB-3608 are prostone-based (prostaglandin analogs) therapeutics that we believe can provide significant pain relief and improvement in neurogenic intermittent claudication (NIC) symptoms for patients suffering from LSS. These therapies represent potential first-in-class treatment options for LSS patients.

Request Information


Please tell us who you are, thanks.
Please let us know your name.
Please let us know your email address.

0/200

Text messaging only, no special coding please.

For information on our Privacy Policy.

Are you a robot?

Request Information

Please complete the form below to be updated on Spine Biopharma

Please tell us who you are, thanks.
Please let us know your name.
Please let us know your email address.

0/200

Text messaging only, no special coding please.

For information on our Privacy Policy.

Are you a robot?